At a glance
ClinicalIndex Comparison RecordN/ACompleted· 818 enrolled
Drug / intervention
Magnetic Resonance Imaging (MRI) +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alzheimer's Disease Neuroimaging Initiative
In Brief
An observational study evaluating Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and 1 other intervention for Alzheimer's Disease. Completed, enrolled 818 participants across 59 sites in 2 countries.
Detailed Summary
The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesCanada, United States
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2005
Enrollment StartJul 2005
Primary CompletionJun 2011
TodayJul 2026
First PostedApr 1, 2005
Enrollment StartJul 1, 2005
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 21.3 years ago
Interventions
Magnetic Resonance Imaging (MRI)procedure
MRI scans
Positron Emission Tomography (PET)procedure
PET scans
Lumbar Puncture (LP)procedure
collection of cerebrospinal fluid